Karyopharm Therapeutics 2022 Cancer Therapy Investor Presentation

Commercial-stage biopharmaceutical company focused on developing novel cancer therapies through nuclear export inhibition. Presents pipeline progress for selinexor (XPOVIO) and eltanexor across multiple indications including multiple myeloma, endometrial cancer, and myelofibrosis, with cash runway into early 2024.